Skip to Main Content

Paper Details

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer Discov
256
2017
B-cell antigen receptor, B-cell antigen receptor-associated protein, B-cell lymphoma of the CNS, BCR, BTK, Bruton Tyrosine Kinase, Bruton tyrosine kinase, CARD11, CD79B, CD79B-mutant PCNSL cells, CD79B-mutant PCNSLs, CD79B-mutant human PCNSLs, CNS lymphoma, Ibrutinib, NF-B, PCNSL, PCNSLs, PI3K, PI3K isoforms, Primary CNS Lymphoma, Toll-like receptors, Tyrosine, diffuse large B-cell lymphoma, human, ibrutinib, mTOR, mammalian target of rapamycin, mammalian target of rapamycin (mTOR)-related gene sets, p110, patients, primary central nervous system (CNS) lymphoma, rapamycin, tumor, tyrosine
Author NameAffiliation
Agnes VialeMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Cameron BrennanMemorial Sloan Kettering Cancer Center
Thomas J KaleyMemorial Sloan Kettering Cancer Center
Thomas J KaleyWeill Cornell Medical College
Minhee Won
Vaios HatzoglouMemorial Sloan Kettering Cancer Center
Jason T HuseMemorial Sloan Kettering Cancer Center
Jason T HuseMemorial Sloan Kettering Cancer Center
Katherine S PanageasMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
  • 1 - 15

Datasets

Release 1.2